Document is current
Any future updates will be listed below
-
Authors
Höglinger, Günter
Vandenberghe, Wim https://orcid.org/0000-0002-9758-5062
Woitalla, Dirk
Corvol, Jean-Christophe
Van Tricht, Hans
Ewen, Colin
Van Den Steen, Bart
Rebollo Mesa, Irene
Germani, Massimiliano
Garric, Elodie
Arnould, Tasmin
Jose, Joby
Strong, Nancy
De Bruyn, Steven https://orcid.org/0009-0001-4853-7339
Buchanan, Tim J https://orcid.org/0000-0003-1218-5420
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04185415 at ClinicalTrials.govnct03068468 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct02985879 at ClinicalTrials.govDocuments that mention this clinical trial
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct03464227 at ClinicalTrials.govDocuments that mention this clinical trial
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct03605082 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct04185415 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct03464227 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct04185415 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct04658199 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct03464227 at ClinicalTrials.govDocuments that mention this clinical trial
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct03605082 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct04658199 at ClinicalTrials.govDocuments that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
nct04185415 at ClinicalTrials.govDocuments that mention this clinical trial
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
Documents that mention this clinical trial
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities
https://doi.org/10.1136/bmjno-2025-001395
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
https://doi.org/10.1136/bmjno-2025-001396
-
Funding
Funding for this research was provided by:
UCB (N/A)
- License Information
